Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ABCL 
Abcellera Biologics Inc (ABCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/27/2025: ABCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -20.34% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 688.35M USD | Price to earnings Ratio - | 1Y Target Price 11.86 |
Price to earnings Ratio - | 1Y Target Price 11.86 | ||
Volume (30-day avg) 3507947 | Beta 0.45 | 52 Weeks Range 2.11 - 4.75 | Updated Date 03/30/2025 |
52 Weeks Range 2.11 - 4.75 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -807.03% |
Management Effectiveness
Return on Assets (TTM) -12.41% | Return on Equity (TTM) -14.75% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 128101515 | Price to Sales(TTM) 23.87 |
Enterprise Value 128101515 | Price to Sales(TTM) 23.87 | ||
Enterprise Value to Revenue 4.44 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 297988000 | Shares Floating 202801468 |
Shares Outstanding 297988000 | Shares Floating 202801468 | ||
Percent Insiders 22.88 | Percent Institutions 42.47 |
Analyst Ratings
Rating 4.56 | Target Price 12.14 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Abcellera Biologics Inc
Company Overview
History and Background
AbCellera Biologics Inc. was founded in 2012. It's a biotechnology company focused on antibody discovery using AI-powered platforms. It initially focused on providing antibody discovery services and has evolved to developing its own therapeutic programs.
Core Business Areas
- Antibody Discovery: Offers end-to-end antibody discovery services, from target selection to lead candidate identification and optimization, using its proprietary microfluidics and AI platform. Focuses on a diverse range of therapeutic targets and indications.
- Therapeutic Development: Advances therapeutic programs, either independently or in collaboration with partners, targeting unmet medical needs, particularly in areas of infectious diseases and oncology.
Leadership and Structure
The leadership team includes Carl Hansen (CEO), and the organizational structure comprises research, development, commercial, and support functions. The company operates with a focus on innovation and collaboration.
Top Products and Market Share
Key Offerings
- Antibody Discovery Platform: AI-powered antibody discovery platform to discover therapeutic antibodies for its partners. Revenue generated from partnerships depends on milestone payments and royalties on potential sales of drugs discovered using its platform. Competitors include distributed lab service providers such as Charles River Laboratories and Thermo Fisher Scientific, and other technology-driven antibody discovery companies such as Ligand Pharmaceuticals.
- Bamlanivimab (LY-CoV555): Monoclonal antibody developed in partnership with Eli Lilly for COVID-19 treatment. While it generated significant revenue initially, its effectiveness against newer variants declined, significantly affecting sales. Competitors include other antibody treatments by Regeneron and AstraZeneca, as well as vaccines developed by Pfizer/BioNTech and Moderna.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, characterized by significant investment in R&D and a focus on innovative therapies. Factors include increasing demand for personalized medicine, advancements in genomics and proteomics, and regulatory changes.
Positioning
AbCellera is positioned as a technology leader in antibody discovery, using AI and high-throughput screening to accelerate the process and identify novel therapeutic candidates. Its competitive advantage lies in its proprietary platform and proven track record of successful partnerships.
Total Addressable Market (TAM)
The TAM for antibody discovery and development is substantial, estimated at billions of dollars annually. AbCellera is positioned to capture a significant share through its technological advantages and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- AI-driven approach
- Successful partnerships with major pharmaceutical companies
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Reliance on partnerships for revenue
- Dependence on the success of partner programs
- Limited direct commercialization capabilities
- High R&D expenses
- Potential for competition from established biotechnology firms
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing proprietary therapeutic programs
- Leveraging platform for new therapeutic modalities
- Entering new markets and geographies
- Advancements in AI and machine learning
Threats
- Competition from established biotechnology companies
- Technological advancements by competitors
- Regulatory changes impacting drug development
- Economic downturns affecting R&D spending
- Patent disputes
Competitors and Market Share
Key Competitors
- CRL
- TMO
- LIGD
- LLY
- REGN
- AZN
Competitive Landscape
AbCellera's technological advantage is balanced by larger, more established competitors with greater resources and broader market reach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by partnership deals, and related milestone revenues. Bamlanivimab impacted growth positively and negatively.
Future Projections: Future growth depends on successful partnerships and advancement of therapeutic programs. Analyst estimates vary, with uncertainty related to drug development success.
Recent Initiatives: Recent initiatives include expanding partnerships, investing in AI infrastructure, and advancing internal therapeutic programs.
Summary
AbCellera is an innovative antibody discovery company with a strong technology platform and valuable partnerships. Revenue streams are variable, and the business depends on research and development. However, with a strong position in AI-powered antibody discovery, Abcellera has the potential for significant long-term growth, but also faces challenges from larger competitors and regulatory uncertainties.
Similar Companies
- CRL
- TMO
- LIGD
- LLY
- REGN
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abcellera Biologics Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-12-11 | CEO, President & Chairperson Dr. Carl L.G. Hansen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 596 | Website https://www.abcellera.com |
Full time employees 596 | Website https://www.abcellera.com | ||
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.